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Abstract
Objective: adrenal masses are incidentally discovered in 5% of cT scans. In 2013/2014, 81 million cT examinations 
were undertaken in the Usa and 5 million in the UK. However, uncertainty remains around the optimal imaging 
approach for diagnosing malignancy. We aimed to review the evidence on the accuracy of imaging tests for 
differentiating malignant from benign adrenal masses.
Design: a systematic review and meta-analysis was conducted.
Methods: We searched MEDLInE, EMBasE, cochrane cEnTRaL Register of controlled Trials, science citation Index, 
conference Proceedings citation Index, and ZETOc (January 1990 to august 2015). We included studies evaluating the 
accuracy of cT, MRI, or 18f-fluoro-deoxyglucose (fDg)-PET compared with an adequate histological or imaging-based 
follow-up reference standard.
Results: We identified 37 studies suitable for inclusion, after screening 5469 references and 525 full-text articles. studies 
evaluated the accuracy of cT (n = 16), MRI (n = 15), and fDg-PET (n = 9) and were generally small and at high or unclear 
risk of bias. Only 19 studies were eligible for meta-analysis. Limited data suggest that cT density >10 HU has high 
sensitivity for detection of adrenal malignancy in participants with no prior indication for adrenal imaging, that is, masses 
with ≤10 HU are unlikely to be malignant. all other estimates of test performance are based on too small numbers.
Conclusions: Despite their widespread use in routine assessment, there is insufficient evidence for the diagnostic 
value of individual imaging tests in distinguishing benign from malignant adrenal masses. future research is urgently 
needed and should include prospective test validation studies for imaging and novel diagnostic approaches alongside 
detailed health economics analysis.
Review
Open Access
www.eje-online.org
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Introduction
An incidentally discovered adrenal mass is a frequent 
occurrence, serendipitously discovered in around 5% 
of cross-sectional abdominal imaging carried out for 
purposes other than a suspected adrenal problem (1, 2, 3). 
Due to the increasingly widespread use of cross-sectional 
imaging, adrenal incidentalomas represent a significant 
challenge to health care budgets. The rates of computed 
tomography (CT) scans carried out in the USA soared 
from 3 million per annum in 1980 to 81.2  million in 
2014 (4). Concurrently, in the UK, 5 million CT scans 
were undertaken in 2012/2013, increasing from 1 million 
in 1996/1997 (www.england.nhs.uk/statistics/statistical-
work-areas/diagnostics-waiting-times-and-activity/
imaging-and-radiodiagnostics-annual-data/). The use 
of repeated and multiple modality imaging in adrenal 
incidentalomas represents a major challenge to health 
care budgets and a burden to patients affected. Therefore, 
evidence-based guidance on the use of imaging in adrenal 
incidentalomas is urgently needed.
Prevalence of adrenal incidentalomas increases with 
age (3% at 40 years, 10% at 70 years) (5), and is very 
low in children (<0.5%) (6). A key consideration for the 
 diagnostic workup of adrenal incidentalomas is whether 
the adrenal mass is hormone-producing, requiring 
exclusion of pheochromocytoma, Cushing syndrome, and, 
in hypertensive patients, primary aldosteronism. Second, 
and usually perceived as most important by the affected 
patient, the possibility of malignancy has to be considered.
In patients with a history of extra-adrenal malignancy, 
the detection of a new adrenal mass raises suspicion of 
metastasis, but also requires careful exclusion of other causes. 
In cancer patients, the likelihood of an adrenal nodule being 
malignant is approximately 20%; eventually, only 70% of 
adrenal lesions surgically removed on the basis of imaging 
results are confirmed as metastasis by histology (7, 8, 9).
While the detection of adrenal metastasis is a rarity 
in adrenal incidentaloma patients who do not have a 
history of extra-adrenal malignancy, the discovery of 
an adrenocortical carcinoma (ACC) is not uncommon. 
Larger clinical and surgical adrenal incidentaloma series 
report an ACC prevalence of 1.4–12% (2, 10, 11, 12), with 
variability mostly driven by referral bias. Radiological 
studies describe lower rates of malignant and functionally 
active adrenal tumors, but usually lack uniform endocrine 
evaluation and an optimal reference standard such that 
malignant lesions could be missed (3).
An adrenal incidentaloma is most frequently noted 
on CT or MRI scans carried out for other purposes. Both 
 imaging modalities can assess the lipid content in the 
adrenal mass, which serves as the basis for differentiating 
between a benign (high lipid content) and a potentially 
malignant (low lipid content) adrenal mass. However, 
at least a third of benign adrenal adenomas have been 
shown to be lipid-poor (13, 14). This lack of specificity 
causes many patients to undergo multiple scans and imag-
ing modalities, often followed by surgery, with histology 
ultimately revealing a benign mass that would not have 
required surgery in 30–55% of patients (2, 15).
In addition to the general radiological criteria of 
size of the mass and its appearance (heterogeneity, 
 borders,  invasion) (13, 16), multiple imaging parameters 
are employed for the differential diagnosis of adrenal 
incidentaloma. These include unenhanced CT with 
assessment of tumor density, contrast-enhanced timed 
washout CT studies, MRI chemical shift analysis, 
and, more recently, 18F-fluoro-deoxyglucose (FDG)-PET 
(FDG-PET) in combination with CT (PET-CT).
However, despite their widespread use in the workup of 
adrenal incidentalomas, the optimal choice, sequence and 
performance of imaging tests to distinguish benign from 
malignant adrenal masses is unclear (17), and clinical prac-
tice remains more expert-based than  evidence-based. Indi-
vidually, published reports are often unconvincing due to 
small sample sizes, heterogeneity of included populations 
and different imaging techniques or cut-offs as well as 
poor reference standards. Due to this, many patients with 
adrenal tumors undergo multiple scans, annual follow-up 
imaging and even unnecessary surgery (2), with previ-
ous guidelines and reviews requesting annual follow-up 
imaging for up to 2 years in most adrenal incidentaloma 
patients not undergoing surgery (16, 17, 18).
We have carried out a systematic review and meta-
analysis of the diagnostic performance of imaging tests 
in incidentally discovered adrenal masses, with the aim 
of facilitating evidence-based recommendations on 
the effective use of imaging in adrenal incidentalomas. 
With advances in the evaluation of diagnostic test accu-
racy increasing the awareness of potential sources of bias 
(19, 20, 21, 22), as well as summarizing study findings, we 
provide insights into the validity and applicability of the 
available evidence base and identify current limitations.
Methods
This review follows methods as set out in the Cochrane 
Handbook for Systematic Reviews of Diagnostic Test 
Accuracy (23) and reporting standards set in the 
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Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) statement (24). This paper reports 
on the accuracy of CT, MRI, and FDG-PET or PET-CT at 
commonly used thresholds for the diagnosis of malignant 
adrenal masses in individuals with incidentally identified 
lesions, including those identified in individuals with 
known malignancy.
Data sources and searches
MEDLINE (Ovid), MEDLINE In Process (Ovid), EMBASE 
(Ovid), Cochrane CENTRAL Register of Controlled Trials 
and Cochrane Database of Systematic Reviews, Science 
Citation Index, and Conference Proceedings Citation 
Index (Web of Science) and ZETOC (British Library) 
databases were searched by an Information Specialist (SB) 
for titles published between 1990 and 13 August 2015. 
Studies published before 1990 were not considered to be 
representative of current imaging technologies. The full 
search strategy as designed for MEDLINE is available in 
Supplementary Table 1, see section on supplementary 
data given at the end of this article. The reference lists 
of included studies and relevant systematic reviews were 
reviewed for additional eligible studies.
Study selection
We considered all studies of CT, MRI, or FDG-PET in adult 
participants with incidentally identified adrenal masses 
for inclusion. These included both patients in whom 
imaging for any indication other than an adrenal mass 
led to the detection of an adrenal mass (true adrenal 
incidentalomas) and patients with an adrenal mass 
detected by imaging carried out for staging or follow-up 
of extra-adrenal malignancy. Studies that did not report 
the original indication for imaging are reported, but were 
not included in the meta-analyses.
The target condition of interest was the detection of 
adrenocortical carcinoma (ACC) or adrenal metastases 
from an extra-adrenal primary malignancy. We included 
all studies with reference standards where i) at least 50% 
of participants with ACC or a malignant adrenal mass 
had a histologically proven reference standard diagnosis 
(obtained either through adrenalectomy or adrenal 
biopsy) and ii) at least 50% of those with a benign adrenal 
mass had their final diagnosis reached by either histology 
or imaging-based follow-up of any duration.
In collaboration with clinical and radiological experts 
from the European Society of Endocrinology (ESE) and 
European Network for the Study of Adrenal Tumors 
(ENSAT) Clinical Practice Guideline Committee for the 
management of adrenal incidentalomas, we selected 
five commonly used diagnostic imaging thresholds for 
inclusion: (i) non-contrast CT: tumor density measured 
in Hounsfield units (HU) >10; (ii) contrast-enhanced CT 
washout studies: absolute percentage washout (APW) 
and/or relative percentage washout (RPW) at any wash-
out percentage or delay time on enhanced CT; (iii) MRI 
chemical shift analysis: loss of signal intensity between in 
and out of phase images (including both qualitative and 
quantitative estimates of signal loss); and, for FDG-PET 
or PET-CT, (iv) the maximum standardized uptake value 
(SUVmax); and (v) the ratio of SUVmax in the adrenal gland 
compared with the liver (adrenal liver ratio (ALR)).
We excluded studies where more than half of 
participants presented with endocrine symptoms, or 
were otherwise suspected of hormone excess, and those 
concerned with the diagnosis of adrenomedullary 
tumors; pheochromocytomas can usually be detected 
by measuring plasma or urinary metanephrines and 
their imaging characteristics overlap with those 
observed in adrenocortical malignancy and adrenal 
metastases. Therefore, studies with more than 30% 
pheochromocytomas in the disease-positive group were 
excluded, unless data could be disaggregated to allow their 
exclusion from the analysis. We also excluded studies in 
pediatric populations, sample size <10, data collection 
before 1990, and with insufficient data presented to allow 
the construction of a 2 × 2 diagnostic contingency table. 
Non-English language studies and studies only reported 
in conference abstracts were excluded.
Title and abstract screening and full-text inclusion 
was carried out independently by two reviewers (I B, J 
Di,). Any disagreements were resolved through discussion 
or referral to a third reviewer (C D, V C, L F R).
Data extraction and quality assessment
Data extraction was carried out independently by at least 
two authors (I B, J Di, L F R, V C, C D) using a standardized 
and piloted data extraction form. Details of the study 
design, participants, lesion characteristics, index test(s) 
or test combinations and index test positivity thresholds, 
reference standards, and 2 × 2 diagnostic contingency 
table data were extracted. Any malignant masses detected 
in addition to ACC or adrenal metastases (malignant 
pheochromocytomas, other malignant medullary tumors 
or other malignancy) were considered disease positive, as 
www.eje-online.org
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their clinical management is sufficiently similar. If study 
data could not be fully disaggregated, the malignant 
group could include up to 10% benign masses and up to 
10% of the benign group could include medullary tumors 
(pheochromocytomas, neuroblastoma, ganglioneuroma, 
or schwannoma). Discrepancies in data extraction were 
resolved by consensus or by a third reviewer.
We considered the risk of bias and concerns about 
the applicability of findings related to the patients, 
tests, reference standard, and execution of each study, 
using the QUADAS-2 checklist (19), tailored to the 
review topic. Three authors (I B and V C plus J Di or L 
F R) independently rated each study with disagreement 
resolved by consensus.
Patient selection was regarded at risk of bias if 
consecutive or random selection was not used, patients 
were selected according to presence of adrenalectomy 
data, or patients were inappropriately excluded based 
on previous lesion assessments. Test and reference 
standard implementation were considered at risk of 
bias when each was undertaken with knowledge of the 
other, or when test thresholds were not prespecified, and 
when final diagnoses of malignancy were not all based 
on histology or tumor sampling was inadequate, or 
benignity was assumed without histology or <12 months 
imaging follow-up. Non-blinded interpretation of other 
imaging tests added to bias in test interpretation. Risk of 
bias in the execution of the study was considered when 
reference standards were not undertaken in all patients, 
when participants were excluded from analyses, when 
the reference standards used in malignant or benign 
cases varied, or when there was no follow-up of suspected 
benign cases within 6 months.
Concerns about applicability were noted for partici-
pants when <90% were recruited with incidentally discov-
ered adrenal tumors or having known or prior malignancy; 
for tests, when inadequate detail of the test measure was 
given to allow replication or standard thresholds were not 
used; and when the reference standard did not allow full 
disaggregation of the tumor types into malignant and 
benign.
Data synthesis and analysis
Data synthesis focused on estimating the accuracy 
of each test for diagnosis of malignancy for separate 
clinical pathways for (i) adrenal incidentaloma, that is, 
investigation of an adrenal tumor detected by imaging 
carried out for an indication other than suspected adrenal 
disease and for (ii) history of extra-adrenal malignancy, 
that is, imaging evaluation or staging in patients with 
known or prior non-adrenal malignancy. It was considered 
possible that the accuracy of each test may differ between 
these clinical pathways. Each study was characterized 
according to whether the majority (>50%) or nearly all 
(>90%) individuals were recruited in each pathway, and 
separate analyses were undertaken for each group. Studies 
that did not meet these criteria or where the reasons for 
imaging could not be ascertained were excluded from the 
analysis. For analysis of MRI chemical shift we restricted 
inclusion to studies using 1.5 Tesla machines, which were 
the majority.
Estimates of sensitivity and specificity and 95% CIs 
for the detection of malignancy were calculated using the 
binomial exact method when there was only one study, 
or when there were no false negatives or false positives. 
Otherwise, the bivariate hierarchical model was used to 
obtain meta-analytical estimates of average sensitivity 
and specificity (25). Where possible, the model included 
terms for random effects for sensitivity and specificity 
and their correlation, but was simplified when inadequate 
numbers of studies were available (26).
Results
Characteristics of included studies
A total of 5496 unique references were identified and 
screened for inclusion. Of these, 525 full-text papers were 
reviewed and 37 studies were included (Fig. 1A) (7, 27, 28, 
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 
60, 61, 62). Studies were primarily excluded due to lack 
of test accuracy data (167 studies), inadequate reference 
standards (93 studies), and ineligible populations (86 
studies). A further 17 studies did not present their data in 
accordance with our review question and it was not possible 
to disaggregate their results to allow their inclusion (i.e. 
>30% pheochromoytomas in the malignant group (n = 8), 
>10% medullary tumors (n = 6) or any malignant mass 
(n = 2) in the benign group, and >10% benign masses in 
the malignant group (n = 1)) and 11 studies were excluded 
as they did not use any of our preselected diagnostic 
thresholds (Supplementary Table 2).
Summary study characteristics are presented in 
Table  1. CT was evaluated in 16 studies (non-contrast 
CT was evaluated in 13 studies, contrast-enhanced CT 
washout studies in 6 studies), MRI in 15 studies, and PET 
in 9 studies. Studies were generally small with a median 
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Figure 1
(a) PRIsMa flow diagram (adapted from Moher 2009 (24)). (B) summary risk of bias and concerns about applicability (based on 
adapted QUaDas-2 (19)).
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sample size of 45 (range 12–181) and less than a third 
were prospective in design (n = 10, 27%). Mean prevalence 
of malignancy was 38% (range 13–74%). Most were con-
ducted in Europe (n = 15, 41%) and North America (n = 12, 
32%). Datasets for a single imaging test were included 
from most studies (n = 34, 92%) compared with a refer-
ence standard of histology alone (n = 14, 38%; excision or 
biopsy sample) or a mixed reference standard of histol-
ogy or imaging follow-up (n = 14, 38%). Reported follow-
up periods ranged from 6 to 24 months. Of the papers 
 reporting participant recruitment dates (n = 27, 76%), 
most were conducted between 2000–2005 (n = 12, 32%) 
and 2005–2009 (n = 9, 24%).
Where reported, study populations were highly 
varied, with only 7 studies (19%) including a majority of 
participants with purely incidental findings and 11 (29%) 
focusing primarily on participants with known extra-
adrenal malignancy (>50% of population) (Table 1). 
Studies variously excluded masses with particular imaging 
characteristics including CT HU < 10 (n = 3), size <10 mm 
Table 1 summary of the characteristics of the 37 studies fulfilling the inclusion criteria.
Characteristic Studies (n) (%)
study design
 Prospective case series 9 (24)
 Retrospective case series 19 (51)
  Diagnostic case–control (two-gate series) 4 (11)
 Design unclear 5 (14)
Population characteristics
 sample size (participants) *50.4 †(12–181)
 sample size (lesions) *52.3 †(14–146)
 Prevalence of malignancy (%) *38.1 †(13–74)
 Mean age (years; 29 studies) ‡*55.8 †(44.1–66.7)
 female participants (%; 31 studies) *49.4 †(6–87)
 Mean tumor size (mm; 24 studies) ‡*41.9 †(22–68.1)
  Mean % symptomatic participants (5 studies) *36 †(26–47)
  confirmed hormone excess (%; 11 studies) *36.3 †(0.02–88)
Index tests and thresholds
 cT 16 (43)
  non-enhanced tumor density 13 (35)
   contrast-enhanced washout studies 6 (16)
 MRI 15 (41)
   chemical shift loss of signal intensity 8 (22)
   adrenal to liver ratio signal intensity 8 (22)
   adrenal to spleen ratio signal intensity 5 (14)
   adrenal to muscle ratio signal intensity 2 (5)
 PET 4 (11)
  sUVmax 3 (8)
  sUVmax adrenal to liver ratio 5 (14)
 PET-cT 5 (14)
  sUVmax 3 (8)
  aLR sUVmax 4 (11)
Population grouping for analysis
  Initial finding incidental in ≥90% included participants 3 (8)
  Initial finding incidental in 50–90% included participants 4 (11)
  Initial indication for imaging due to known cancer in ≥90%  
included participants
9 (24)
  Initial indication for imaging due to known cancer in 50–90%  
included participants
2 (5)
  Initial finding incidental in <50% OR <50% imaging  
indication known cancer
2 (5)
  Population composition not reported 17 (46)
Reference standard
 Histology alone 16 (43)
 Histology and imaging follow-up 15 (41)
  Histology and imaging follow-up, plus other reference 5 (14)
 Histology plus other reference 1 (3)
sUVmax, maximum standardized uptake value; aLR sUVmax, ratio of sUVmax in the adrenal gland compared with the liver.
*Mean; †Range; ‡Mean of reported means.
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(n = 11), pheochromocytomas (n = 15), or functioning 
masses (n = 5). Patients with symptoms of hormone excess 
were explicitly included in five studies and confirmed 
hormone excess following imaging was identified in 
around a third of participants (mean 36%, range 0–88%; 
n = 11 studies). Mean tumor size ranged from 19 mm (42) 
to 68 mm (55).
Study quality
The vast majority (84%) of studies were at high or unclear 
risk of bias across all quality domains assessed (Fig. 1A and 
Supplementary Figs 1, 2, 3). A third of studies (n = 12) only 
included participants selected for adrenalectomy and 
therefore at higher risk of malignancy, and four adopted 
a case–control type approach with separate selection of 
those with confirmed malignancy and benign disease 
(33, 39, 49, 53). PET (Supplementary Fig. 3) and MRI 
evaluations (Supplementary Fig. 2) were at particular risk 
of bias due to retrospective selection of the diagnostic 
threshold (in 8/9 and 6/15 evaluations, respectively), 
potentially leading to inflated estimates of test accuracy. 
Test interpretation could have been influenced by the 
same observer interpreting more than one imaging test 
in the same study (affecting 14 of 40 evaluations). Test 
interpretation was blinded to the reference standard 
diagnosis in around half of all test evaluations (52%; 
21/40) and differential verification was present in 62% 
(23/37). More than half of studies used an inadequate 
reference standard either due to the use of biopsy rather 
than full excision of malignant masses (n = 15, 40%) or 
imaging follow-up of <12 months (n = 6, 16%). Concerns 
around the applicability of study results were high (n = 8) 
or unclear (n = 17) due to varying or unclear indications 
for imaging in the included populations and due to the 
evaluation of a new threshold, not previously assessed 
in other studies (present or unclear in 21 of 40 test 
evaluations).
Results according to clinical pathway
Poor reporting of the clinical pathways leading to the 
conduct of the imaging tests resulted in exclusion of 
19 of 37 eligible studies from analysis (described in 
Supplementary Table 3). Characteristics of the 18 studies 
eligible for analysis are provided according to clinical 
pathway in Table 2 and results of test performance are 
reported in Table 3, with raw data for all test evaluations 
provided in Supplementary Table 4.
Test performance in the investigation of incidentally 
detected tumors
Seven studies presented data on test performance (two 
for CT (27, 30), three for MRI (28, 31, 46), and two for 
PET-CT (29, 61)) in patient groups presenting with more 
than 50% (and two with >90%) incidentally detected 
tumors. Two studies evaluating tumor density >10 HU on 
non-contrast CT (27, 30), and one evaluating CT contrast-
enhanced washout tests (27) showed high sensitivity 
and specificity. Only two (28, 31) of the three studies of 
MRI used 1.5 Tesla machines and reported slightly lower 
sensitivity and specificity than CT for measures of adrenal-
liver and adrenal-spleen ratios and loss of signal intensity. 
The performance of PET for ALR and SUVmax measures was 
no better than CT.
The data suggest that CT density >10 HU has high 
sensitivity for the detection of malignancy, the 95% CI 
suggesting that this is above 90%. However, all other 
estimates of test performance are based on small numbers 
of studies with few patients, and 95% CIs are notably 
wide, indicating uncertainty in test performance for all 
other imaging markers. It is not possible to discern from 
the available data whether any test performs adequately 
or better than alternative tests.
Test performance in the investigation of tumors 
in participants with current or prior non-adrenal 
malignancy
Eleven studies presented data on test performance (five for 
CT (7, 33, 34, 35, 37), five for MRI (32, 34, 35, 36, 60), and 
three for PET-CT (8, 38, 62)) in patient groups presenting 
with more than 50% (and 9 with >90%) tumors detected 
in patients undergoing imaging following previous non-
adrenal malignancy. The five studies evaluating CT density 
>10 HU on non-contrast CT (7, 33, 34, 35, 37) showed 
high sensitivity (93%) but variable specificity; CT contrast-
enhanced washout tests were only reported in one study 
(33), which showed very low sensitivity (16%). Four (32, 34, 
36, 60) of the five studies of MRI used 1.5 Tesla machines 
and reported high  sensitivity (89–99%) for measures of 
adrenal-liver, adrenal-spleen, adrenal-muscle ratios and 
loss of signal intensity. Specificity varied (60–93%) but was 
high for most MRI measures. The performance of PET was 
similar to MRI for ALR and SUVmax measures.
Although more studies had evaluated CT, MRI, and 
PET in the pathway for follow-up of known malignancy 
than for incidentally discovered adrenal lesions, estimates 
of test performance are still based on too small numbers 
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of studies to be able to discern whether any test per-
forms adequately or better than alternative tests from the 
 available data.
Discussion
Our main finding cautiously suggests that in patients 
without known extra-adrenal malignancy, a non-contrast 
CT tumor density of 10 HU is a diagnostically relevant 
cut-off, albeit based only on data from two small studies. 
The sensitivity of >10 HU for detecting malignancy was 
high (100%; 95% CI: 91, 100%), however, the specificity 
was poor. Conversely, this means that an incidentally 
discovered adrenal mass with a non-contrast CT tumor 
density of ≤10 HU is unlikely to be malignant. Tumor 
density ≤10 HU was less conclusive for ruling out 
malignancy in patients with a history of extra-adrenal 
malignancy, however, with a pooled false-negative rate 
of 7%, although CIs were wide. With positive predictive 
values for detection of malignancy in the order of 70–80% 
in both populations, a considerable number of adrenal 
masses with tumor density >10 HU are likely to be benign. 
Table 3 Test performance according to clinical pathway. studies focusing on truly incidentally discovered adrenal masses 
(incidentaloma pathway) vs studies on adrenal masses discovered during follow-up monitoring for extra-adrenal malignancy 
(follow-up from previous malignancy pathway).
≥ 50%* ≥90%**
studies (n/N) sensitivity (95% cI) specificity (95% cI) studies (n/N) sensitivity (95% cI) specificity (95% cI)
Incidentaloma pathway
 cT non–contrast tumor  
  density (>10 HU)
2 (41/102) 100% (91–100%) 72% (60–82%) 1 (13/52) 100% (75–100%) 72% (55–85%)
 cT contrast enhanced  
  washout (combination at 
  10 min)
1 (14/25) 93% (68–100%) 100% (69–100%) 0 – –
 cT contrast enhanced  
  washout (combination at 
  15 min)
1 (13/25) 100% (75–100%) 92% (62–100%) 0 –
 MRI adrenal-liver ratio  
  (1.5 Tesla only)
1 (8/26) 100% (63–100%) 44% (22–69%) 0 – –
 MRI adrenal-spleen ratio  
  (1.5 Tesla only)
1 (12/49) 58% (28–85%) 86% (71–95%) 0 – –
 MRI loss of signal intensity  
  (1.5 Tesla only)
2 (20/75) 86% (31–99%) 85% (73–93%) 0 – –
 PET aLR sUVmax 2 (15/64) 100% (78–100%) 96% (57–100%) 1 (12/41) 100% (74–100%) 100% (88–100%)
 PET sUVmax 2 (15/64) 93% (65–99%) 73% (59–84%) 1 (12/41) 92% (62–100%) 72% (53–87%)
follow-up from previous malignancy pathway
 cT non–contrast tumor  
  density (>10 HU)
5 (93/168) 93% (79–98%) 71% (38–91%) 5 (93/168) 93% (79–98%) 71% (38–91%)
 cT contrast enhanced  
  washout (absolute at  
  15 min)
1 (19/40) 16% (3–40%) 86% (64–97%) 1 (19/40) 16% (3–40%) 86% (64–97%)
 cT contrast enhanced  
  washout (relative at  
  15 min)
1 (19/40) 16% (3–40%) 95% (76–100%) 1 (19/40) 16% (3–40%) 95% (76–100%)
 MRI adrenal-liver ratio  
  (1.5 Tesla only)
3 (37/129) 89% (74–96%) 60% (21–89%) 2 (27/93) 92% (55–99%) 39% (21–60%)
 MRI adrenal-spleen ratio  
  (1.5 Tesla only)
3 (52/142) 99% (69–100%) 84% (72–91%) 2 (42/105) 100% (92–100%) 79% (68–88%)
 MRI adrenal-muscle ratio  
  (1.5 Tesla only)
1 (10/37) 90% (55–100%) 93% (76–99%) 0 – –
 MRI loss of signal intensity  
  (1.5 Tesla only)
1 (10/37) 90% (55–100%) 85% (66–96%) 0 – –
 PET aLR sUVmax 2 (45/117) 82% (41–97%) 96% (76–99%) 1 (34/102) 94% (80–99%) 94% (86–98%)
 PET sUVmax 3 (72/156) 84% (62–94%) 90% (71–97%) 2 (61/141) 90% (80–96%) 87% (78–93%)
aLR sUVmax, ratio of sUVmax in the adrenal gland compared with the liver; HU, Hounsfield units; n, number of cases; N, total population; PET, positron 
emission tomography; sUVmax, maximum standardized uptake value.
*refers to ≥50% with incidentaloma in studies in the incidentaloma pathway and ≥50% with current or prior non-adrenal malignancy in the follow-up 
from previous malignancy pathway; **refers to ≥90% with incidentaloma in studies in the incidentaloma pathway and ≥90% with current or prior 
non-adrenal malignancy in the follow-up from previous malignancy pathway.
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These and all other pooled estimates have such wide CIs 
that no further conclusions can be drawn regarding the 
accuracy of imaging tests for the detection of malignancy 
in incidentally discovered adrenal masses.
Possible clinical explanations for this uncertainty 
include variability in the lipid content of adenomas, tis-
sue heterogeneity, small size of metastatic lesions, or 
differences in selecting regions of interest for HU measure-
ment. However, most of the uncertainty is due to small 
numbers of eligible studies and hence results from few 
patients available for analysis. Despite the availability of a 
significant number of studies addressing imaging charac-
teristics in patients with an adrenal mass, more than 90% 
of full-text papers retrieved had to be excluded. Many had 
small sample sizes, mixed populations, inadequate report-
ing on imaging techniques and thresholds, as well as 
unacceptable reference standards for both malignant and 
benign masses. Even with our stringent eligibility criteria, 
included studies were characterized by heterogeneity in 
study populations, imaging tests and thresholds, and ref-
erence standards as well as poor methodological quality. 
Given differences in patient spectrum according to the 
indication for adrenal imaging and the potential impact 
on accuracy (63, 64, 65), our meta-analysis was further 
restricted to studies where a majority of participants had 
either incidentaloma or were undergoing imaging due to 
known malignancy, leading to the exclusion of another 
50% of included studies. Heterogeneity in study conduct 
and poor methodological quality remained, further con-
tributing to the lack of certainty in pooled estimates.
Our findings are disappointingly consistent with 
another systematic review of the literature on tests for 
adrenal incidentaloma published almost 15 years ago 
(66). Observed heterogeneity in tests and populations 
meant that no meta-analysis was undertaken and no clear 
conclusions could be drawn (66). Almost three-quarters 
(27/37) of the studies in our review were published in the 
interim period; however, methodological and reporting 
quality have not improved sufficiently to allow any new 
conclusions to be drawn. A more recent meta-analysis of 
FDG-PET (67) applied considerably less stringent inclu-
sion criteria compared with our review, thereby including 
more studies (n = 21); however, highly heterogeneous data 
limited the conclusions that could be drawn.
Our findings of poor quality and reporting of test 
accuracy studies are similar to findings from other fields 
(68, 69, 70). Introduction of the Standards for Reporting 
Diagnostic Accuracy (STARD) statement (71) has only led 
to small improvements in reporting (72) and our results 
indicate that greater awareness is required of methodological 
considerations in the design and delivery of multicenter 
studies in this field, as in many others, to improve reporting.
The strengths of this review include an in-depth 
comprehensive literature search, a focused review ques-
tion, and stringent predefined reference standard. The 
limitations were derived from the heterogeneity and low 
quality of included studies. Unclear definitions of study 
populations, various and often data-driven thresholds, as 
well as different techniques for the same imaging tests, 
limit the interpretation and generalization of results. The 
weak conclusions derived from this systematic review and 
meta-analysis should be interpreted in relation to the low 
volume and poor quality of included studies (Fig. 1B).
Our results do not suggest that current imaging prac-
tice is inappropriate: small study numbers prevent us from 
providing substantive evidence to either support current 
practice or to prompt a need for a change in imaging prac-
tice. We suggest further studies are needed to answer the 
following key questions:
1. Do adrenal lesions with unenhanced CT tumor 
density ≤10 HU need additional imaging, in particular 
in patients with a history of extra-adrenal malignancy?
2. What is the best second-line imaging study that would 
accurately diagnose (or exclude) a malignant adrenal 
mass?
3. What additional factors influence decisions on imag-
ing choice? (patient preference, radiation risks, costs)
4. How much tumor growth, and over what period of 
time, is indicative of a malignant adrenal mass?
In addition, future studies should include the systematic 
evaluation of alternative testing approaches and detailed 
analysis of health economics impact. All these questions 
can only be answered with larger multicenter studies, with 
prospective recruitment of consecutive series of participants 
in appropriately defined clinical pathways, and imaging test 
interpretation blinded to the reference standard diagnosis 
and to the result of any other imaging tests. Diagnostic 
thresholds for determining benignity or malignancy must 
be prespecified to avoid data-driven threshold selection 
and overestimation of test accuracy. The reliance on a 
histological reference standard leads to study populations 
with a high pretest probability of malignancy, however, 
imaging follow-up of those with indeterminate imaging 
characteristics needs to be long enough to ensure that 
malignant masses are not missed. Centralized radiological 
and pathology review would further help to strengthen the 
results. Future investigators must also meet the updated 
STARD recommendations (20) so that study conduct and 
quality can be judged appropriately.
www.eje-online.org
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In conclusion, current evidence on imaging tests and 
cut-offs in diagnosis of incidentally discovered adrenal mass 
is highly heterogeneous and disappointingly poor. Not 
surprisingly, many patients with adrenal incidentaloma 
undergo repeated multimodal imaging and even unnecessary 
adrenalectomy. With adrenal incidentalomas detected 
on 1 in 20 (1, 2, 3) of an ever-increasing number of cross-
sectional abdominal imaging studies performed every year, 
the potential economic and health impact of unnecessary 
procedures and interventions could be significant. In this 
era of evidence-based medicine, and with advances in our 
understanding of optimal diagnostic test accuracy study 
design and study synthesis, it is incumbent on the medical 
community to provide a solid evidence base to underpin 
imaging practice in this field. Areas of uncertainty especially 
include second-line testing for indeterminate adrenal masses 
and larger adrenal masses, with very limited data on CT 
washout, MRI, and PET-CT. Further well-designed studies 
are needed to establish performance and health economic 
impact of imaging in patients with incidentally discovered 
adrenal masses.
This meta-analysis has informed the ESE-ENSAT 
Clinical Guidelines on the management of adrenal 
incidentalomas (73).
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